Industry Newsgenome editingprecision genetic drugsbeam therapeuticsanalyst coverage
Beam Therapeutics Receives Broker Price Target Boosts
7.1
On Jan. 7, 2026, Bernstein kept an Outperform rating for Beam Therapeutics and raised its price target from $37 to $41 after a favorable Alpha-1 Antitrypsin Deficiency (AATD) regulatory update. On the same day UBS initiated coverage with a neutral rating and a $28 target, citing improving biotech fundamentals; revised AATD data expected in Q1 2026 could act as a catalyst.
Key Points
- 1Raises: Bernstein lifts Beam price target to $41 citing a favorable AATD regulatory update.
- 2Notes: UBS initiates neutral coverage at $28 amid improving biotech fundamentals and investor confidence.
- 3Implication: Revised AATD data due Q1 2026 could materially affect Beam's valuation and investor sentiment.
Scoring Rationale
Broker ratings and upcoming Q1 AATD data drive relevance; limited novelty beyond routine analyst coverage constrains novelty.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
